Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
127.99
-0.05 (-0.04%)
Apr 28, 2026, 2:53 PM EDT - Market open
Neurocrine Biosciences Analyst Ratings
Total Analysts
22
Consensus Rating
Strong Buy
Price Target
$180.91
Upside
+41.35%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $160 → $170 | Buy | Maintains | $160 → $170 | +32.82% | Apr 22, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $173 → $185 | Hold | Maintains | $173 → $185 | +44.54% | Apr 10, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $204 → $242 | Strong Buy | Maintains | $204 → $242 | +89.08% | Apr 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $164 → $200 | Strong Buy | Maintains | $164 → $200 | +56.26% | Apr 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $151 → $166 | Buy | Maintains | $151 → $166 | +29.70% | Apr 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $192 → $215 | Strong Buy | Maintains | $192 → $215 | +67.98% | Apr 7, 2026 |
| Needham | Needham | Strong Buy Reiterates $185 | Strong Buy | Reiterates | $185 | +44.54% | Apr 6, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $176 → $177 | Buy | Maintains | $176 → $177 | +38.29% | Mar 12, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates $160 | Buy | Initiates | $160 | +25.01% | Feb 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $177 → $176 | Buy | Maintains | $177 → $176 | +37.51% | Feb 17, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $169 → $140 | Strong Buy | Maintains | $169 → $140 | +9.38% | Feb 17, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $180 → $175 | Buy | Maintains | $180 → $175 | +36.73% | Feb 13, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $203 → $204 | Strong Buy | Maintains | $203 → $204 | +59.39% | Feb 12, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $180 → $177 | Buy | Maintains | $180 → $177 | +38.29% | Feb 12, 2026 |
| BMO Capital | BMO Capital | Hold Maintains $147 → $140 | Hold | Maintains | $147 → $140 | +9.38% | Feb 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $149 → $151 | Buy | Maintains | $149 → $151 | +17.98% | Feb 12, 2026 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.